James Chih-Hsin Yang

35PUBLICATIONS
254CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsRadiation and matterPsychophysiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Feb 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Rachel Woodford, Sally Lord, Tom John

|Feb 17, 2026
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Ben Tran, Mark Voskoboynik, Sang-We Kim

|Dec 01, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Pascale Tomasini, Yongsheng Wang, Yongsheng Li

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Jul 29, 2025
The Prognostic Role of Tertiary Lymphoid Structures and Immune Microenvironment Signatures in Early-Stage EGFR-Mutant Lung Adenocarcinoma.

Wei-Hsun Hsu, Chia-Chi Hsu, Min-Shu Hsieh

|Jul 24, 2025
Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Derek De-Rui Huang, James Chih-Hsin Yang

Pageof 6

Frequent Collaborators

8 joint publications

Pasi A Jänne

6 joint publications

Yi-Long Wu

6 joint publications

Enriqueta Felip

6 joint publications

Byoung Chul Cho